Original articleNephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations
Section snippets
Overview
The core methodology was to divide the consideration of clinical and histopathological criteria between two sets of expert physicians (clinicians and pathologists). These teams were tasked with developing objective criteria for diagnosis and identifying exclusionary criteria based on the differential diagnosis of NSF. The teams identified criteria within their purview (drawing on professional experience, the medical literature, and the resources of the NSF registry3) and developed clinical and
Results
The results of this work consist of a recommended clinical and histopathological diagnostic evaluation for patients in whom NSF is suspected, a clinical and pathological scoring system keyed to an atlas of visual standards, and a diagnostic grid that combines the clinical and pathological scores to recommend a final diagnosis. These are detailed in Table IV, Table V, Table VII, Table VIII, Table IX, Table X, Table VI and Fig 1, Fig 2, Fig 3, Fig 4, Fig 5, Fig 6, Fig 7, Fig 8, Fig 9, Fig 10, Fig
Renal disease
See Table IV. Prevailing theories regarding the development of NSF are based on the observation that disease onset and activity depend on underlying renal dysfunction. This dysfunction could be characterized as a decreased rate of or absent glomerular filtration, either acutely or chronically. Because this concept is so powerfully ingrained in the medical literature about NSF, the authors concluded that any cases defined as “consistent with” or “diagnostic of” NSF without a known history of
References (23)
- et al.
Scleromyxedema-like cutaneous diseases in renal-dialysis patients
Lancet
(2000) - et al.
Nephrogenic fibrosing dermopathy: two pediatric cases
J Pediatr
(2003) Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy
Am J Kidney Dis
(2005)- et al.
Nephrogenic fibrosing dermopathy with recurrence after allograft failure
J Am Acad Dermatol
(2007) - et al.
Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis
J Am Acad Dermatol
(2007) - et al.
Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies
Autoimmun Rev
(2008) - et al.
Immunochemical analysis of the monoclonal paraprotein in scleromyxedema
J Invest Dermatol
(1978) - et al.
Nephrogenic fibrosing dermopathy
Am J Dermatopathol
(2001) - Cowper SE. International Nephrogenic Systemic Fibrosis Registry 2001-2011. Available from: URL: http://www.icnsfr.org....
- et al.
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Crit Care
(2007)
Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
Nephrol Dial Transplant
Cited by (131)
Adverse Events Associated with Intra-Arterial Administration of Gadolinium-Based Contrast Agents: A Systematic Review and Meta-Analysis
2023, Journal of Vascular and Interventional RadiologySnapshotDx Quiz: April 2021
2021, Journal of Investigative DermatologyRisks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review
2021, American Journal of Kidney DiseasesPseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 – Radiological features and metric markers
2021, Critical Reviews in Oncology/Hematology
Please visit http://www.eblue.org for the unabridged version of this manuscript.
This project was coordinated by ACR Image Metrix, an American College of Radiology–owned company. Funding for the project was provided to ACR Image Metrix equally by the following organizations: Bayer HealthCare, Bracco, Covidien, and GE HealthCare.
Conflicts of interest: None declared.